Evidence map›Paper›PMID 30349641›Full record

ArticleOncotarget2018

Characterization of murine CEACAM1

Robbie L McLeod, Minilik H Angagaw, Toya Nath Baral, Liming Liu, Raymond Joseph Moniz, Jason Laskey, SuChun Hsieh, Mike Lee, Jin-Hwan Han, Hassan Issafras and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. The emerging role of Fusobacteria in carcinogenesis.European journal of clinical investigation · 2024
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Robbie L McLeodMerck & Co., Inc., Boston, MA, USA.
Minilik H AngagawMerck & Co., Inc., Boston, MA, USA.
Toya Nath BaralMerck & Co., Inc., Boston, MA, USA.
Liming LiuMerck & Co., Inc., Boston, MA, USA.
Raymond Joseph MonizMerck & Co., Inc., Boston, MA, USA.
Jason LaskeyMerck & Co., Inc., Boston, MA, USA.
SuChun HsiehMerck & Co., Inc., Boston, MA, USA.
Mike LeeMerck & Co., Inc., Boston, MA, USA.
Jin-Hwan HanMerck & Co., Inc., Boston, MA, USA.
Hassan IssafrasMerck & Co., Inc., Boston, MA, USA.
Sarah JavaidMerck & Co., Inc., Boston, MA, USA.
Andrey LobodaMerck & Co., Inc., Boston, MA, USA.
Svetlana SadekovaMerck & Co., Inc., Boston, MA, USA.
Joann A O'ConnorMerck & Co., Inc., Boston, MA, USA.
Archie TseMerck & Co., Inc., Boston, MA, USA.
Juha PunnonenMerck & Co., Inc., Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has been reported to mediate both tumorigenic and anti-tumor effects

Indexed as

CC1CD8+ T cellsCEACAM1pharmacokineticsyngeneic mouse model

Identifiers

PMID30349641
PMCPMC6195382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.